Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2015

01.12.2015

Ocular Involvement of Behçet’s Syndrome: a Comprehensive Review

verfasst von: Yilmaz Ozyazgan, Didar Ucar, Gulen Hatemi, Yusuf Yazici

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Behçet’s syndrome (BS) is a vasculitis involving several organ systems including the eyes. Ocular involvement is one of the most disabling complications of BS, causing loss of vision that may progress to blindness if left untreated. The typical form of ocular involvement is a relapsing and remitting panuveitis and retinal vasculitis. Initial attacks may spontaneously improve and subsequently disappear in a few weeks but tend to recur if left untreated. Destructive and recurrent attacks, especially with posterior segment and retina involvement, may cause irreversible ocular structural changes and permanent damage in sensory retina, resulting in loss of vision. The risk of irreversible damage to ocular tissue which may result in loss of vision warrants early and intensive treatment especially in patients at high risk such as young men who tend to follow an aggressive disease course. The management strategy involves rapid suppression of inflammation during the attacks and prevention of recurrent attacks. Local and systemic measures including immunosuppressives, corticosteroids, and biologic agents are used for this purpose. Surgery may be required in selected cases. The prognosis of eye involvement has greatly improved over the last decades with the effective use of immunosuppressives.
Literatur
1.
Zurück zum Zitat Tugal-Tutkun I, Gupta V, Cunningham ET (2013) Differential diagnosis of Behçet uveitis. Ocul Immunol Inflamm 21(5):337–350CrossRefPubMed Tugal-Tutkun I, Gupta V, Cunningham ET (2013) Differential diagnosis of Behçet uveitis. Ocul Immunol Inflamm 21(5):337–350CrossRefPubMed
2.
Zurück zum Zitat Tugal-Tutkun I, Onal S, Ozyazgan Y, Soylu M, Akman M (2013) Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behçet uveitis. Ocul Immunol Inflamm. 2013 Dec 11. [Epub ahead of print] Tugal-Tutkun I, Onal S, Ozyazgan Y, Soylu M, Akman M (2013) Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behçet uveitis. Ocul Immunol Inflamm. 2013 Dec 11. [Epub ahead of print]
3.
Zurück zum Zitat Yurdakul S, Yazıcı Y (2010) Epidmiology of Behçet’s syndrome and regional differences in disease expression. In: Yazıcı H, Yazıcı Y (eds) Behçet’s syndrome. Springer, New York, pp 35–52 Yurdakul S, Yazıcı Y (2010) Epidmiology of Behçet’s syndrome and regional differences in disease expression. In: Yazıcı H, Yazıcı Y (eds) Behçet’s syndrome. Springer, New York, pp 35–52
4.
Zurück zum Zitat Mishima, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) Behçet’s disease in Japan: ophthalmological aspect. Trans Am Ophthalmol Soc 77:225–279PubMedCentralPubMed Mishima, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) Behçet’s disease in Japan: ophthalmological aspect. Trans Am Ophthalmol Soc 77:225–279PubMedCentralPubMed
5.
Zurück zum Zitat Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A (2008) Clinical features of Chinese patients with Behçet’s disease. Ophthalmology 115(2):312–318.e4CrossRefPubMed Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A (2008) Clinical features of Chinese patients with Behçet’s disease. Ophthalmology 115(2):312–318.e4CrossRefPubMed
6.
Zurück zum Zitat Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148–155CrossRefPubMed Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148–155CrossRefPubMed
7.
Zurück zum Zitat Kazokoğlu H, Onal S, Tuğal-Tutkun İ et al (2008) Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 15:285–293CrossRefPubMed Kazokoğlu H, Onal S, Tuğal-Tutkun İ et al (2008) Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 15:285–293CrossRefPubMed
8.
Zurück zum Zitat Yazıcı H, Tüzün Y, Pazarlı H et al (1984) Influence of age of onset and patient’s sex on the prevalence and severity of manifestation of Behçet’s syndrome. Ann Rheum Dis 43:783–789PubMedCentralCrossRefPubMed Yazıcı H, Tüzün Y, Pazarlı H et al (1984) Influence of age of onset and patient’s sex on the prevalence and severity of manifestation of Behçet’s syndrome. Ann Rheum Dis 43:783–789PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Kural-Seyahi E, Fresko İ, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60–76CrossRefPubMed Kural-Seyahi E, Fresko İ, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60–76CrossRefPubMed
10.
Zurück zum Zitat Tuğal-Tutkun I, Onal S, Altan-Yaycioğlu R, Hüseyin Altunbaş H, Urgancioğlu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed Tuğal-Tutkun I, Onal S, Altan-Yaycioğlu R, Hüseyin Altunbaş H, Urgancioğlu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed
11.
Zurück zum Zitat Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516CrossRefPubMed Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516CrossRefPubMed
12.
Zurück zum Zitat Pazarlı H, Ozyazgan Y, Aktunc T (1989) Clinical observations on hypopyon attacks of Behçet’s disease in Turkey. In: Seventh international conference on Behçet’s disease (abstracts), Rochester. MN. 14–15 Sept Pazarlı H, Ozyazgan Y, Aktunc T (1989) Clinical observations on hypopyon attacks of Behçet’s disease in Turkey. In: Seventh international conference on Behçet’s disease (abstracts), Rochester. MN. 14–15 Sept
13.
Zurück zum Zitat Nussenblatt RB, Whitcup SM, Palestine AG (2004) Behçet’s disease. In: Nussenblatt RB, Whitcup SM, Palestine AG (eds) Uveitis: fundamentals and clinical practice. Mosby, Philadelphia, pp 350–371 Nussenblatt RB, Whitcup SM, Palestine AG (2004) Behçet’s disease. In: Nussenblatt RB, Whitcup SM, Palestine AG (eds) Uveitis: fundamentals and clinical practice. Mosby, Philadelphia, pp 350–371
15.
Zurück zum Zitat Mullaney J, Collum LM (1985) Ocular vasculitis in Behçet’s disease: a pathological and immunohistochemical study. Int Ophthalmol 7:183–191CrossRefPubMed Mullaney J, Collum LM (1985) Ocular vasculitis in Behçet’s disease: a pathological and immunohistochemical study. Int Ophthalmol 7:183–191CrossRefPubMed
16.
Zurück zum Zitat Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arc Ophthalmol 84:451–452CrossRef Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arc Ophthalmol 84:451–452CrossRef
17.
Zurück zum Zitat Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I (2012) Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 20(6):423–428CrossRefPubMed Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I (2012) Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 20(6):423–428CrossRefPubMed
18.
Zurück zum Zitat Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541CrossRefPubMed Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541CrossRefPubMed
19.
Zurück zum Zitat Yazıcı H, Pazarlı H, Barnes CG et al (1990) A controlled trail of azathioprine in Behçet’s syndrome. N England J Med 322:281–285CrossRef Yazıcı H, Pazarlı H, Barnes CG et al (1990) A controlled trail of azathioprine in Behçet’s syndrome. N England J Med 322:281–285CrossRef
20.
Zurück zum Zitat Hamuryudan V, Ozyazgan Y, Hızlı N et al (1997) Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774CrossRefPubMed Hamuryudan V, Ozyazgan Y, Hızlı N et al (1997) Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774CrossRefPubMed
21.
Zurück zum Zitat Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Işcimen A, Tuzun Y et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243PubMedCentralCrossRefPubMed Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Işcimen A, Tuzun Y et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Masuda K, Nakajima A, Urayama A, Nakae K et al (1989) Double-masked trial of cyclosporin versus colchicines and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096CrossRefPubMed Masuda K, Nakajima A, Urayama A, Nakae K et al (1989) Double-masked trial of cyclosporin versus colchicines and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096CrossRefPubMed
23.
Zurück zum Zitat BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporin A in Behçet’s syndrome. Transplant Proc 20(3 Suppl 4):136–143PubMed BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporin A in Behçet’s syndrome. Transplant Proc 20(3 Suppl 4):136–143PubMed
24.
Zurück zum Zitat Durand JM, Soubeyrand J (1994) Interferon-alpha 2b for refractory ocular Behçet’s disease. Lancet 344:333CrossRefPubMed Durand JM, Soubeyrand J (1994) Interferon-alpha 2b for refractory ocular Behçet’s disease. Lancet 344:333CrossRefPubMed
25.
Zurück zum Zitat Kotter I, Eckstein AK, Stübiger N et al (1998) Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488–494PubMedCentralCrossRefPubMed Kotter I, Eckstein AK, Stübiger N et al (1998) Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488–494PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Kotter I, Zıerhut M, Eckstein AK, VontheinR NT, Gunaydın I et al (2003) Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431PubMedCentralCrossRefPubMed Kotter I, Zıerhut M, Eckstein AK, VontheinR NT, Gunaydın I et al (2003) Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Kotter I, Deuter C, Stubiger N, Zierhut M (2005) Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet’s disease: focusing more on IFN. J Rheumatol 32:1633PubMed Kotter I, Deuter C, Stubiger N, Zierhut M (2005) Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet’s disease: focusing more on IFN. J Rheumatol 32:1633PubMed
28.
Zurück zum Zitat Tugal –Tutkun I, Güney–Tefekli E, Urgancioğlu M (2006) Results of interferon-alpha therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695CrossRefPubMed Tugal –Tutkun I, Güney–Tefekli E, Urgancioğlu M (2006) Results of interferon-alpha therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695CrossRefPubMed
29.
Zurück zum Zitat Bodaghi B, Gendron G, Wechsler B (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335–339PubMedCentralCrossRefPubMed Bodaghi B, Gendron G, Wechsler B (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335–339PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Onal S, Kazokoglu H, Koc A et al (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 129:288–294CrossRefPubMed Onal S, Kazokoglu H, Koc A et al (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 129:288–294CrossRefPubMed
31.
Zurück zum Zitat Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296CrossRefPubMed Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296CrossRefPubMed
32.
Zurück zum Zitat Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed
33.
Zurück zum Zitat Tugal-Tutkun I, Mudun A, Urgancıoğlu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroid in Behçet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484CrossRefPubMed Tugal-Tutkun I, Mudun A, Urgancıoğlu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroid in Behçet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484CrossRefPubMed
34.
Zurück zum Zitat Bodaghi B, Bui Quoc E, Wechsler B et al (2005) Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 64:962–964PubMedCentralCrossRefPubMed Bodaghi B, Bui Quoc E, Wechsler B et al (2005) Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 64:962–964PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741CrossRef Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741CrossRef
36.
Zurück zum Zitat Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21:824–825CrossRefPubMed Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21:824–825CrossRefPubMed
37.
Zurück zum Zitat Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP (2011) A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford) 50(3):593–597CrossRef Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP (2011) A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford) 50(3):593–597CrossRef
38.
Zurück zum Zitat Okada AA, Goto H, Ohno S, Mochizuki M (2012) Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 130(5):592–598CrossRefPubMed Okada AA, Goto H, Ohno S, Mochizuki M (2012) Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 130(5):592–598CrossRefPubMed
39.
Zurück zum Zitat Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M (2010) Regression of optic disc neovascularization in patients with Behçet’s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 26(6):627–630CrossRefPubMed Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M (2010) Regression of optic disc neovascularization in patients with Behçet’s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 26(6):627–630CrossRefPubMed
40.
Zurück zum Zitat Keino H, Okada AA, Watanabe T, Taki W (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 95(9):1245–1250CrossRefPubMed Keino H, Okada AA, Watanabe T, Taki W (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 95(9):1245–1250CrossRefPubMed
41.
Zurück zum Zitat Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye (Lond) 21(6):824–825CrossRef Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye (Lond) 21(6):824–825CrossRef
42.
Zurück zum Zitat Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 18(3):226–232CrossRefPubMed Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 18(3):226–232CrossRefPubMed
43.
Zurück zum Zitat Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71(4):563–566CrossRefPubMed Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71(4):563–566CrossRefPubMed
44.
Zurück zum Zitat Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D, Emmi L (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153PubMed Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D, Emmi L (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153PubMed
45.
Zurück zum Zitat Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589–1591CrossRefPubMed Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589–1591CrossRefPubMed
Metadaten
Titel
Ocular Involvement of Behçet’s Syndrome: a Comprehensive Review
verfasst von
Yilmaz Ozyazgan
Didar Ucar
Gulen Hatemi
Yusuf Yazici
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2015
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-014-8425-z

Weitere Artikel der Ausgabe 3/2015

Clinical Reviews in Allergy & Immunology 3/2015 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Bilateraler Hörsturz hat eine schlechte Prognose

15.04.2024 Hörsturz Nachrichten

Die Mehrzahl der Menschen mit Hörsturz ist einseitig betroffen, doch auch ein beidseitiger Hörsturz ist möglich. Wie häufig solche Fälle sind und wie sich ihr Verlauf darstellt, hat eine HNO-Expertenrunde aus den USA untersucht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.